食道がんに対するドセタキセル+シスプラチン+フルオロウラシル療法における急性腎障害発症の予測因子の検討

抄録

The docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen is considered to be one of the treatment choices for esophageal cancer. Acute kidney injury (AKI) is one of the side effects of cisplatin, and the onset of AKI limits the use of cisplatin. However, the factors influencing the onset of AKI remain unknown. Therefore, we examined retrospectively the new factors influencing the onset of AKI in patients with DCF therapy. This study included forty-four cases, and nine cases (20.5％) had the onset of AKI. We examined clinical laboratory values before treatment as the factors influencing the onset of AKI. The incidence of AKI in patients whose serum β₂-microglobulin values were above the upper limit of normal values (2.0 mg/L) was 42.9％ (6/14) and significantly high (P = 0.019). As a result of this study, it was revealed that serum β₂-microglobulin is a new useful marker predicting the onset of CDDP-induced AKI.